Venetoclax plus chemo to change cancer cell behavior
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial tests whether venetoclax, combined with chemotherapy and a “cancer cell behavior” medicine strategy, can improve treatment for people with AML that has come back or not gone into remission. It’s mainly looking at safety and early signs of benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML (or a related leukemia) that has relapsed or did not respond to prior treatment, and your bone marrow has enough measurable leukemia cells
- You can be in the trial even if leukemia is in the brain/CNS or other outside-the-bone areas, but cranial (head) radiation is not allowed during study treatment
- Your overall health is strong enough for treatment: adult (age >16) Karnofsky score over 50% or child (≤16) Lansky score over 50%
- You’ve recovered from prior treatment side effects, with specific “time since last treatment” waiting periods depending on what you had
- Your kidneys, liver, and heart function are strong enough based on blood tests and heart measurements
- You can safely take infection prevention antifungal medicine during treatment, and you do not have certain active or recent serious fungal infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.